Oh snap, Vinay Prasad criticizes the Yale Paxlovid for LC trial. His main criticism is the decision to give ritonavir to the ‘placebo’ group.
His second criticism is that the study is underpowered. If Pfizer funds enough of these studies, they will eventually have a study with “positive” results that would justify the use of Paxlovid for “Long COVID”. (They have an incentive to create big markets for their drugs so their Long COVID definition would be a loose definition where many people would qualify as having “Long COVID”.)